Generics Body Attacks WHO's 'Immature' Biological Qualifier Scheme
This article was originally published in SRA
Executive Summary
The World Health Organization's 'biological qualifier' scheme has its supporters and its detractors, with the former believing it will improve drug use and monitoring, and the latter thinking it at best superfluous and at worst a potential source of confusion and regulatory misalignment.
You may also be interested in...
WHO To Pilot ‘Biological Qualifier’ Scheme Despite Protests From Biosimilars Industry
The World Health Organization has decided to pursue its “Biological Qualifier” scheme despite concerns that it may conflict with other traceability systems. Calls by the European biosimilars industry to put the scheme on ice appear to have fallen on deaf ears.
WHO To Pilot ‘Biological Qualifier’ Scheme Despite Protests From Biosimilars Industry
The World Health Organization has decided to pursue its “Biological Qualifier” scheme despite concerns that it may conflict with other traceability systems. Calls by the European biosimilars industry to put the scheme on ice appear to have fallen on deaf ears.
EU Health Chief Under Pressure To Explain Delay In Legislative Overhaul
The latest delay to the European Commission’s proposals for revising the EU medicines legislation has caused consternation among members of the European Parliament who do not believe that the hold-up is due simply to a “busy agenda” at the commission.